Goodwin Biotechnology, Inc.

MEDTECH

Avenge Bio, Inc. | August 23, 2022

Avenge Bio, Inc. a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced a publication in the peer-reviewed journal Clinical Cancer Research describing the foundational, preclinical data establishing the efficacy and safety of pleural administered LOCOcyte™ for the treatment of pleural malignant mesothelioma. The manuscript, entitled "Activation of adaptive...

PR Newswire | June 08, 2020

For biopharma companies seeking increased development and manufacturing capacity for vaccines and therapies, including new COVID-19-related programs, Thermo Fisher Scientific provided highlights of its new capabilities during the BIO International Convention, June 8-12, now a virtual event at www.bio.org/events/bio-digital."We can now provide an uninterrupted path from development to commercialization for biopharma companies, small to large, in geographies worldwide and across vaccine...

CELL AND GENE THERAPY

Rocket Pharmaceuticals, Inc. | September 21, 2022

Rocket Pharmaceuticals, Inc. a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, and Renovacor, Inc. a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced a definitive agreement under which Rocket will acquire Re...

BioSpace | February 20, 2020

Bladder cancer drug Padcev, which was approved by the U.S. Food and Drug Administration in December, secured Breakthrough Therapy designation for the treatment of patients with another type of bladder cancer. Seattle Genetics and Astellas Pharma, the co-developers of Padcev (enfortumab vedotin-ejfv) said the new designation was awarded to the bladder cancer drug in combination with Merck’s checkpoint inhibitor Keytruda for the treatment of patients with unresectable locally advanced or met...